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Introduction
Esophageal cancer is a highly aggressive malignant 
disease with a 5-year survival rate of 10% to 15% (Ferri 
et al., 2012). The incidence of esophageal cancer varies 
greatly between populations and across geographic 
regions. The Taihangshan Mountain area, including 
Linxian in Henan Province, a rural area of China, has 
the highest incidence of esophageal cancer, especially 
squamous cell carcinoma (ESCC), in the world (>100 per 
100, 000 population) (Zhang et al., 2011; Lin et al., 2013). 
Inflammation has been recognized as a contributing 
factor for the pathogenesis of ESCC. There are 
results showing that two key inflammatory enzymes, 
Phospholipase A2 Group IIA (PLA2G2A) and 
cyclooxygenase-2 (COX-2) are involved in the pathways 
of arachidonic acid (AA) biosynthesis, and both play an 
important role in inflammation and angiogenesis as well 
as cancer (Murakami et al., 2011). Recently, we reported 
that PLA2G2A and COX-2 gene single nucleotide 
polymorphisms (SNPs) may modify the risk of ESCC 
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development (Liu et al., 2014). However, the relationship 
between PLA2G2A and COX-2 protein expression and 
ESCC clinical features remains controversial in the 
literature (Li et al., 2009;Ren et al., 2013). Moreover, a 
correlation between the co-expression of PLA2G2A and 
COX-2 in ESCC has not yet been reported.
The present study aimed to evaluate the relationship 
between PLA2G2A and COX-2 expression in ESCC, 
and to determine if co-occur between these two proteins 
are correlated with a set of well-known clinical and 
pathological features of esophageal carcinoma in a high-
risk Chinese population.
Materials and Methods
Patients and tissue samples
This case-control study consecutively recruited a total 
of 290 primary esophageal squamous cell carcinoma 
patients, who underwent surgical resection of primary 
ESCC at the Yaocun County hospital in Linxian, Henan 
Province, China from October 2009 to September 2010. 
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Lymph node status was determined through biopsy. Tumor 
stage was determined according to the AJCC TNM criteria 
(Edge et al., 2009), 38 cases were stage I, 137 cases 
were stage II, 97 cases were stage III and 18 cases were 
stage IV. The 290 cancerous and 30 paired noncancerous 
tissues from these patients were routinely fixed in 10% 
buffered formalin and blocked in paraffin, and embedded 
in paraffin blocks for histological procedures and 
immunohistochemical staining. None of the patients had 
received chemo cancer therapy before surgery. 
The study was approved by the Institutional Review 
Board of Capital Medical University (Beijing, China), and 
all subjects gave written informed consent.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using 
the streptavidin-biotin method. Four-micrometer-thick 
sections of representative blocks from each case were 
deparaffinized in xylene, rehydrated, and treated with 3% 
hydrogen peroxide for 10 minutes to block endogenous 
peroxidase activity. All sections were subjected to heat-
induced epitope retrieval by autoclaving sections in a 
10mM citrate buffer (pH6.0) for 10 minutes. After cooling 
to room temperature, the sections were treated with 3% 
hydrogen peroxide for 5 minutes followed by application 
of the primary antibody and then incubated at 4°C 
overnight. The antibodies used were rabbit anti-human 
PLA2G2A polyclonal antibody (ab23705, 1:200; Abcam, 
Cambridge, MA, USA) and mouse anti-human COX-2 
monoclonal antibody (1:100; Cayman Chemical Co., Ann 
Arbor, MI). The sections that were tested for PLA2G2A 
and COX-2 IHC were incubated with polyperoxidase-
anti-mouse/rabbit immunoglobulin (GBI) for 30 minutes 
at 37°C, and antibody-binding sites were visualized by 
DAB kit (Zhongshan Golden Bridge Co., Beijing, China). 
Non-immune serum instead of the primary antibody was 
used as negative control.
Evaluation of immunohistochemistry
The immunohistochemical expression of PLA2G2A 
and COX-2 was examined independently by 2 
pathologists. The percentage of positive cells was graded 
semiquantitatively, and each sample was assigned to one 
of the following categories: grade 1, <5% cells showed 
immunoreactivity; grade 2, 5%-30% positive cells; and 
grade 3, >30% positive cells. For final statistical analysis, 
positive expression was defined as cells with grade 2 or 
above (≥5%) expression levels. 
Statistical analysis
All statistical analyses were performed using SPSS 
software version 13.0 (SPSS Inc., Chicago, IL, USA). 
The distribution between the expression of COX-2 or 
PLA2G2A and the clinical and pathological features 
of ESCC patients was evaluated using Chi-squared or 
Fisher’s exact test. The agreement between expression 
of COX-2 and PLA2G2A was assessed by consistency 
test. The relationship between the two biomarkers co-
expression and the clinical and pathological features of 
patients was determined using Spearman’s rank order 
correlation coefficients. Two sided significance tests 
were used throughout, p≤0.05 was considered statistically 
significant.
Results 
Background of all patients is shown in Table 1. A 
total of 290 patients, including 202 (69.7%) males and 88 
(30.3%) females, were included in this study. The mean 
age of patients was 59.46±7.95 years old. 
PLA2G2A protein expression in primary esophageal 
cancer 
PLA2G2A protein expression in esophageal cancer 
tumor specimens was determined by immunohistochemistry. 
Figure 1. Representative Immunostaining of COX-
2 and PLA2G2A in Esophageal Cancerous and 
Noncancerous Tissues. A) Positive staining for PLA2G2A 
in esophageal tumor tissues. B) Negative staining in normal 
esophageal mucosa. C) Positive staining for COX-2 in 
esophageal tumor tissues.Original magnifications ×400 (A, B 
and C)
A)                                                        B)
C)
Table 1. Comparison of Characteristics in ESCC Patients from High-Risk Linxian County, China
Characteristics N(%)                           PLA2G2A n(%)  p*                              COX-2 n(%)  p*
  Negative Positive  Negative Positive 
Gender Male 202(69.7) 90(72.6) 112(67.5) 0.35 23(69.7) 179(69.6) 0.99
 Female 88(30.3) 34(27.4) 54(32.5)  10(30.3) 78(30.4) 
Age(years) <60 143(49.3) 64(51.6) 79(47.6) 0.49 13(39.4) 130(50.6) 0.23
 ≥60 147(50.7) 60(48.4) 87(52.4)  20(60.6) 127(49.4) 
Smoking Yes 181(62.4) 78(62.9) 103(62.0) 0.88 20(60.6) 161(62.6) 0.82
 No 109(37.6) 46(37.1) 63(38.0)  13(39.4) 96(37.4) 
Drinking Yes 107(36.9) 50(40.3) 57(34.3) 0.29 17(51.5) 90(35.0) 0.06
 No 183(63.1) 74(59.7) 109(65.7)  16(48.5) 167(65.0) 
*Chi-squared test
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As shown in Figure 1A, PLA2G2A immunoreactivity 
was localized mainly in the cytoplasm. The intensity of 
PLA2G2A staining was remarkably higher in primary 
esophageal carcinoma than in matched normal mucosa 
(Figure 1B), which nearly had absent staining. Prevalence 
of PLA2G2A expression positivity was found in 166 of 
290 (57.2%) cancers and 1 of 30 (3.3%) non-cancerous 
tissues (p<0.001). 
Moreover, increased immunoreactivity of PLA2G2A 
in advanced tumor invasion was also observed (p=0.001). 
No significant correlation between PLA2G2A expression 
was observed for the degree of tumor differentiation, 
histological types, T class, lymph node metastasis or tumor 
stage in this case-control study (Table 2). 
COX-2 protein expression in primary esophageal cancer
COX-2 protein expression in esophageal cancer tumour 
specimens was also determined by immunohistochemistry. 
As shown in Figure 1C, COX-2 immunoreactivity was 
also localized mainly in the cytoplasm. The intensity 
of COX-2 staining was remarkably higher in primary 
esophageal carcinoma than in matched normal mucosa, 
high levels of COX-2 expression were found in 257 of 
290 (88.6%) cancers and 3 of 30 (10.0%) non-cancerous 
tissues (p<0.001). 
There was no significant correlation between 
the expression rate of COX-2 with the clinical and 
pathological features in ESCC (Table 2). 
Co-expression of PLA2G2A and COX-2 in ESCC
To determine the degree of co-expression of PLA2G2A 
and COX-2 in ESCC, we divided the 290 patients into 
4 groups: (1) PLA2G2A and COX-2 positive group 
[PLA2G2A (+)/COX-2 (+) group], n=153 (52.7%); (2) 
PLA2G2A positive only group [PLA2G2A (+)/COX-2 
(-) group], n=13 (4.5%); (3) COX-2 positive only group 
[PLA2G2A (-)/COX-2 (+) group], n=104 (35.9%); and (4) 
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Table 4. Comparison of Characteristics in ESCC 
Patients between the COX-2(+)/PLA2G2A(+) and all 
other Groups Combined
Characteristics COX-2 (+)/PLA2G2A (+) Other groups p*
   group (n=153), n (%) (n=137), n (%)
Gender Male 101 (66.0) 101 (73.8) 0.15
 Female 52 (34.0) 36 (26.2) 
Age <60 72 (47.1) 71 (51.8) 0.42
 ≥60 81 (52.9) 66 (48.2) 
Smoking Yes 92(60.1) 89(65.0) 0.39
 No  61(39.9 48(35.0) 
Drinking Yes 49(32.0) 58(42.3) 0.07
 No  104(68.0) 79(57.7) 
*Chi-squared test
Table 5. Comparison of Pathological Features between 
the COX-2(+)/PLA2G2A(+) and all other Groups 
Combined
Diagnosis COX-2(+)/ Other groups p*
  PLA2G2A(+)  (n=137), n(%)
  group (n=153), n(%)
Differentiation   0.86
 Well 29 (19.0) 23 (16.8) 
 Moderated 74 (48.4) 66 (48.2) 
 Poorly 50 (32.6) 48 (35.0) 
Histological types   0.41
 Intramucosal cancer 4 (2.6) 6 (4.4) 
 Invasive cancer 149 (97.4) 131 (95.6) 
Depth of invasion   0.004#
 T1 16 (10.5) 31 (22.6) 
 T2 30 (19.6) 14 (10.2) 
 T3+T4 107 (69.9) 92 (67.2) 
Lymph node   0.37
metastasis
 Negative 78 (51.0) 77 (56.2) 
 Positive 75 (49.0) 60 (43.8) 
Metastasis   0.09
 Negative 147(54.0) 125(46.0) 
 Positive 6(33.3) 12(66.7) 
TNM stages   0.04#
 Ⅰ 14 (9.2) 24 (17.5) 
 Ⅱ 77 (50.3) 60 (43.7) 
 Ⅲ 56 (36.6) 41 (30.0) 
 Ⅳ 6 (3.9) 12 (8.8) 
*Chi-squared or Fisher’s exact test.#Significant at the level of p<0.05.
Table 3. Relation between the Protein Expression of 
COX-2 and PLA2G2A in ESCC 
COX-2 expression PLA2G2A expression n(%) Kappa p*
 Positive Negative  
 n=166 n=124  
Positive 153(59.5) 104(40.5) 0.091 0.03
Negative 13(39.4) 20(60.6)  
*Consistency test, Significant at the level of p<0.05
Table 2. Association of PLA2G2A and COX-2 Expression with Pathological Features in ESCC
Diagnosis  N(%)                       PLA2G2A n (%)  p*                      COX-2 n (%)  p*
   Negative Positive  Negative Positive 
Differentiation Well 52(17.9) 18(14.5) 34(20.5) 0.42 7(21.2) 45(17.5) 0.56
 Moderated 140(48.3) 62(50.0) 78(47.0)  13(39.4) 127(49.4) 
 Poorly 98(33.8) 44(35.5) 54(32.5)  13(39.4) 85(33.1) 
Histological types Intramucosal cancer 10(3.4) 6(4.8) 4(2.4) 0.26 2(6.1) 8(3.1) 0.38
 Invasive cancer 280(96.6) 118(95.2) 162(97.6)  31(93.9) 249(96.9) 
Depth of invasion T1 47(16.2) 30(24.2) 17(10.2) 0.001# 9(27.3) 38(14.8) 0.13
 T2 44(15.2) 12(9.7) 32(19.3)  6(18.2) 38(14.8) 
 T3+ T4 199(68.6) 82(66.1) 117(70.5)  18(54.5) 181(70.4) 
Lymph node metastasis Negative 155(53.4) 71(57.3) 84(50.6) 0.26 17(51.5) 138(53.7) 0.81
 Positive 135(46.6) 53(42.7) 82(49.4)  16(48.5) 119(46.3) 
Metastasis Negative 272(93.8) 115(92.7) 157(94.6) 0.52 30(90.9) 242(94.2) 0.47
 Positive 18(6.2) 9(7.3) 9(5.4)  3(9.1) 15(5.8) 
TNM stages Ⅰ 38(13.1) 23(18.5) 15(9.0) 0.08 7(21.2) 31(12.1) 0.38
 Ⅱ 137(47.2) 56(45.2) 81(48.8)  12(36.4) 125(48.6) 
 Ⅲ 97(33.4) 36(29.0) 61(36.7)  11(33.3) 86(33.5) 
 Ⅳ 18(6.3) 9(7.3) 9(5.4)  3(9.1) 15(5.8) 
*Chi-squared or Fisher’s exact test.#Significant at the level of p<0.05
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both PLA2G2A and COX-2 negative group [PLA2G2A 
(-)/COX-2 (-) group], n=20 (6.9%). We found a significant 
co-expression of PLA2G2A and COX-2 (Kappa=0.09, 
p=0.03) (Table 3). 
Further, we divided the 290 patients into another 2 
sub-groups:  the (PLA2G2A (+)/COX-2 (+) group and the 
other three groups combined.The clinical background of 
these 2 groups is provided in Table 4. We found that the 
PLA2G2A (+)/COX-2 (+) group was significantly more 
advanced with regard to the depth of invasion (p=0.004) 
and TNM stage (p=0.04) (Table 5), compared with the 
other three combined groups.
Discussion
Previous studies have shown that the incidence of 
esophageal chronic inflammation is very high in high-risk 
populations for esophageal cancer, and that the mortality 
of ESCC is closely related with the high incidence of 
chronic inflammation (Savage et al., 2004; Liu et al., 
2014). Thus, it suggested that chronic inflammation 
may be an important precancerous esophageal lesion. In 
the present study, we investigated the expression of the 
inflammatory proteins PLA2G2A and COX-2 in ESCC 
patients; in particular we examined the correlation of 
these two biomarkers with clinical and pathological data, 
in order to determine if the dysregulation of the proteins 
could be associated with ESCC.
Our results showed a moderate increase (57.2%) 
in PLA2G2A expression in ESCC, and PLA2G2A 
overexpression in ESCC correlated with greater mucosa 
invasion potential (p=0.001), which is contrary to at least 
one other report (Ren et al., 2013). Although the reasons 
for this difference remain to be elucidated, dysregulation 
of the PLA2G2A protein might cause carcinogenesis 
through multiple mechanisms (Jiang et al., 2002; Fijneman 
et al., 2008; Wang et al., 2013). The pro-tumorigenic (e.g., 
prostate cancer (Jiang et al., 2002; Graham et al., 2008)) 
or anti-tumorigenic effects (e.g., gastric cancer (Leung et 
al., 2002; Ganesan et al., 2008;Xing et al., 2011; Wang et 
al., 2013)) of PLA2G2A appear to be tissue specific, as 
well as in human intestinal cancer, the role of PLA2G2A 
remains elusive. Several studies have reported both up- 
and down-regulation of PLA2G2A expression in human 
colorectal cancers (MacPhee et al., 1995; Cormier et al., 
1997; Cormier et al., 2000). 
A few in vitro studies further demonstrated that 
PLA2G2A expression induces the proliferation of human 
astrocytoma and esophageal adenocarcinoma cells, and 
treatment with specific PLA2G2A inhibitors or gene 
knockdown attenuates tumor growth (Martin et al., 2009; 
Mauchley et al., 2010). Consequently, PLA2G2A has been 
proposed as a target for the treatment of human cancer 
(Cummings, 2007; Scott et al., 2010). 
COX-2 enzyme is one of the two isoforms of 
cyclooxygenase (COX) producing prostaglandins from 
arachidonic acid. COX-2 levels have been found to be 
high in various tumors (Liu et al., 2006; Gomes et al., 
2013; Peng et al., 2013; Tabriz et al., 2013). This protein 
has an important role in carcinogenesis by promoting 
increased cell proliferation, reducing apoptosis and 
acting in angiogenesis (Takedo, 1998). Our results show 
a significant increase (88.6%) in COX-2 expression in 
ESCC, as previously reported (Gomes et al., 2013). We 
found no significant correlation of COX-2 with tumor 
data. However, both PLA2G2A (+)/COX-2 (+) group was 
significantly more advanced with regard to the depth of 
invasion (P=0.004) and TNM stage (p=0.04) (Table 5), 
PLA2G2A and COX-2 co-occur with ESCC and that are 
characterized by inflammation. These results suggested 
that the activation of eicosanoid metabolic pathway is 
one of the important predictive factors of esophageal 
cancer. It has been known that disruption of the mouse 
PLA2G2A, a potential source of AA for COX-2, increases 
tumor number despite the fact that the mutation has been 
predicted to decrease prostaglandin production (Hong KH, 
et al., 2001). Some studies have suggested that PLA2G2A 
and COX-2 play a role in other diseases (Galecki et al., 
2012). 
Previously we have shown that functional SNPs 
(rs11644) in the genes encoding PLA2G2A and COX-
2 (rs12042763) confer susceptibility to develop ESCC 
(Liu et al., 2014). Therefore, one might conclude that 
the increased expression for PLA2G2A and COX-2 
established in the present study might be genotype 
dependent. There is no evidence for a relation between the 
PLA2G2A and COX-2 gene SNPs and expression (data 
not shown). The variant might be in linkage disequilibrium 
with other variants that affect expression. The expression 
might also be related to another completely different 
variant and increased expression might be circumstances. 
The increased level of PLA2G2A and COX-2 in the ESCC 
tissue might explain their effectiveness of non-steroid 
anti-inflammatory drugs (NSAID) as prevention and 
therapies for ESCC.
In summary, PLA2G2A and COX-2 might play 
an important role in the progression of ESCC, as co-
expression of PLA2G2A and COX-2 correlates with not 
only the depth of invasion but also TNM stage. The precise 
mechanisms underlying the risk effect of PLA2G2A and 
COX-2 interaction on depth of invasion remain to be 
elucidated in further cell- and population-based studies.  
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